On October 11, 2023, the American Society of Clinical Oncology (ASCO) recommended an update to its treatment guidelines for small cell lung cancer (SCLC). Cosela (trilaciclib) has been recommended as a myeloid supportive agent for individuals with extensive-stage SCLC who are receiving treatment with chemotherapy or chemoimmunotherapy.

Myelosuppression or bone marrow suppression (when bone marrow does not make enough blood cells or platelets), is a common side effect for individuals receiving chemotherapy and increases the risk of blood disorders such as anemia (low red blood cell count), bleeding, or infection. The updated guidelines offer doctors a new way to manage this potentially harmful side effect of chemotherapy for persons receiving treatment for SCLC.

Read the full update to ASCO’s treatment guidelines here.